Skip to main content
Equibles
AARD logo

AARD · Aardvark Therapeutics, Inc. · Metrics

Track AARD — free

Use AARD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.13 +0.12 (+2.40%) At close · Sep 11
Rebalance outlook locked
Market Cap
$112.27M
Shares
21.88M

AARD metrics

51 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.13
Market cap
$112.27M

Price action

20 metrics
Price change (1W)
-4.6%
Price change (30D)
-21.6%
Price change (3M)
+31.5%
Price change (6M)
+0.8%
Price change (YTD)
-60.9%
Price change (1Y)
-34.1%
Trailing year
Price change (5Y)
—
52-week high
$17.41
52-week low
$3.48
Change from 52-week high
-70.5%
Change from 52-week low
+47.4%
Annualized volatility
128.1%
Annualized volatility (3M)
159.3%
Beta
3.3
RSI (14D)
39.9
Price vs SMA 50
-18.5%
Price vs SMA 200
-34.8%
Avg volume (3M)
255,091
Relative volume
1.1
Average dollar volume
$1.57M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
21.88M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.5
reciprocal yield 66.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-62.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$73.95M
Net income (TTM)
−$69.89M
Trailing 12 months
Diluted EPS (TTM)
$-3.21
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.89

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-93.4%
Return on assets
-85.8%
Debt / equity
—
Current ratio
12.6
EBITDA (TTM)
−$73.91M
Free cash flow (TTM)
—
Quick ratio
12.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$73.87M
Latest balance sheet
Cash & equivalents
$73.85M
Total assets
$81.46M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$69.41M
Capital expenditures (TTM)
$4,000
R&D (TTM)
$55.06M
SG&A (TTM)
—
Stock compensation (TTM)
$7.04M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
71
13F filer change QoQ
-9
Institutional ownership
43.5%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$394,957
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1774857 CUSIP 002942100 13F (30d) 25 filings 25 filers Visit website Investor relations